Sponsor Check › Person
Named as an officer, director or promoter on SEC Form D filings · CA, WA, MA · Sep 3, 2010 → Dec 22, 2025
Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:15 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET
Peter Bisgaard is listed as a director on 30 SEC Form D filings by 15 issuers between Nov 2009 and Dec 2025. Largest by amount reported sold: MapLight Therapeutics, Inc. (Redwood City, CA — biotechnology — 2019–2025; $188.2M reported sold to 19 investors), Bolt Biotherapeutics, Inc. (Redwood City, CA — biotechnology — 2016; $93.5M reported sold to 17 investors), Eargo, Inc. (San Jose, CA — other health care — 2017–2019; $81.6M reported sold to 41 investors), Outpost Medicine, LLC (Indianapolis, IN — industry reported as "Other" — 2016–2017; $56M reported sold to 11 investors), Light Sciences Oncology Inc (Bellevue, WA — biotechnology — 2009–2012; $35.1M reported sold to 17 investors) and 10 more (all listed below).
What this means That is a lot of deals — 15 separate companies raised money with this person listed as director, over about 16 years. Across those companies the filings report $614.9M sold in total.
Listed alongside Christopher A Kroeger (8 shared filings), George Pavlov (8 shared filings), James Lillie (7 shared filings), Jonathan Gillis (7 shared filings), Robert Malenka (7 shared filings) and 87 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Peter. Each name links to their own page.
The issuers belong to 2 sponsor groups: Pivotal Bioventure (5 issuers, $299.1M reported sold, 2017–2021) and Zacharon (2 issuers, $24.2M reported sold, 2010–2012).
What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 7 court cases matching the name, 8 bankruptcy cases matching the name listed in Key records below.
What this means 15 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 30 public filings for Peter Bisgaard and found 14 differences, 2 worth asking the sponsor about: Paid seller listed without a CRD number: Gateway Private Markets (HK) Limited; Peter Bisgaard is no longer listed on the Oct 12, 2018 amendment; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.
Community search for Peter Bisgaard has not run yet — it is #24,099 of 26,782 in line; searches run around the clock at the hosts' allowed rate. Searched so far: 638 names.
Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).
Five things investors ask first. Items still in human review are counted, not shown.
7 cases: 2 closed (disposition not in docket feed), 4 dismissed, 1 judgment
190 Contract: Other· Cause:
28:1332 Diversity-Contract Dispute
190 Contract: Other· Cause:
28:1332 Diversity-Other Contract
890 Other Statutory Actions· Cause:
28:1331 Fed. Question
Bankruptcy Appeal (801)· Cause:
28:1334 Bankruptcy Appeal
190 Other contract actions
Contract: Other· Cause:
28:1332 Diversity-Breach of Contract
190 Other contract actions
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:15 AM ET.
Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: VA (crawled Oct 23, 2026)
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Peter Bisgaard..
State securities regulators: Securities regulators searched (3,318 actions): AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE DOJ Investor Protection Unit (257 actions, 1987–2026), TX State Securities Board (586 actions, 2006–2026), WA DFI (2,039 actions, 2001–2026) — last crawled Oct 23, 2026, 9:57 PM ET. No machine-readable public listing today for CO, FL, IA, IN, MN, NE, NJ, NY, OH, UT, VA (see docs/state-regulators.md).
8 cases: 1 open, 7 closed (disposition not in docket feed)
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:15 AM ET.
Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons cover issuers and sponsor groups — see the issuer pages under Deals
14 differences found between the filings for Peter Bisgaard — 2 worth asking about (compared 30 filings on Oct 24, 2026)
United States Bankruptcy Court, W.D. Washington docket "Moldt v. US Bank NA" filed Jun 12, 2013, closed Nov 12, 2013. Peter Moldt (listed on the same filings) is listed as Plaintiff ("Moldt"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
United States Bankruptcy Court, C.D. California docket "James A. Trenkle" filed Oct 26, 1994, closed Dec 19, 1994. Jim Trenkle (listed on the same filings) is listed as Debtor ("James A. Trenkle"). Our match estimate: 65%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
OncXerna Therapeutics, Ltd. (last filing Mar 4, 2022; $30,000,000 sold of $100,000,000). Each has no filing in more than two years and reported under half its target sold.
What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.
Gateway Private Markets (HK) Limited is listed as receiving sales compensation on 1 filing (Apr 23, 2021) with no FINRA CRD number given.
What this means People paid to sell securities normally hold a FINRA registration with a CRD number. Without one we cannot look them up on BrokerCheck. Ask who they are and whether they are registered.
The filing says the first sale was Oct 25, 2022. The Form D was filed Nov 10, 2022 — 16 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 1 days past that.
What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.
The filing says the first sale was Aug 10, 2021. The Form D was filed Aug 27, 2021 — 17 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 2 days past that.
What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.
No amendment in the last 12 months on an offering that may still be open — MapLight Therapeutics, Inc. (latest filing Jul 28, 2025) · No amendment in the last 12 months on an offering that may still be open — MapLight Therapeutics, Inc. (latest filing Nov 3, 2023) · No amendment in the last 12 months on an offering that may still be open — OncXerna Therapeutics, Ltd. (latest filing Mar 4, 2022) · No amendment in the last 12 months on an offering that may still be open — Pivotal bioVenture Partners CNS Fund I SLP, L.P. (latest filing Aug 27, 2021) · No amendment in the last 12 months on an offering that may still be open — MapLight Therapeutics, Inc. (latest filing Mar 10, 2021) · and 7 more
What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.
Peter Bisgaard appears on the May 30, 2017 Form D (director) but not on the Oct 12, 2018 Form D/A for the same offering.
What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.
Offering amount changed between filings — MapLight Therapeutics, Inc. · Offering amount changed between filings — Outpost Medicine, LLC · Offering amount changed between filings — Eargo, Inc. · Offering amount changed between filings — Ceterix Orthopaedics, Inc. · Offering amount changed between filings — Altheos, Inc. · and 1 more
What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.
listed as "Peter Bisgaard" on 26 filings (from Nov 5, 2009), and "Peter Tuxen Bisgaard" on 4 filings (from Oct 16, 2017).
What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.
This page covers filings where the address state is CA or WA or MA. A separate record, "Peter Bisgaard" with address state AZ, is listed on 6 filings — most recently by HTG MOLECULAR DIAGNOSTICS, INC (Jan 23, 2015). Both records have filings in the same period (Mar 1, 2011 to Jan 23, 2015).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
This page covers filings where the address state is CA or WA or MA. A separate record, "Peter Bisgaard" with address state G7, is listed on 3 filings — most recently by THESAN PHARMACEUTICALS, INC. (Feb 24, 2014). Both records have filings in the same period (Sep 3, 2010 to Feb 24, 2014).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
Address moved from San Francisco, CA to Redwood City, CA — MapLight Therapeutics, Inc. · Address moved from Moffett Field, CA to San Francisco, CA — MapLight Therapeutics, Inc. · Address moved from Mountain View, CA to San Jose, CA — Eargo, Inc. · Address moved from Lexington, MA to Indianapolis, IN — Outpost Medicine, LLC
What this means Businesses move. If you were told one city and the forms say another, ask which is current.
WA on 3 filings (Nov 5, 2009 to Jan 23, 2012); CA on 23 filings (Sep 3, 2010 to Dec 22, 2025); MA on 4 filings (Jul 23, 2015 to Mar 4, 2022).
What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.
What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.
0 of 24 offerings report sales commissions; 1 reports finder's fees totalling $20,000; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)
| Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it | Source |
|---|---|---|---|---|---|
| Dec 22, 2025 D Addition Therapeutics, Inc. File 021-567798 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 28, 2025 D MapLight Therapeutics, Inc. File 021-552922 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 3, 2023 D/A MapLight Therapeutics, Inc. File 021-487390 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 10, 2022 D MapLight Therapeutics, Inc. File 021-464468 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 4, 2022 D OncXerna Therapeutics, Ltd. File 021-435862 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 27, 2021 D Pivotal bioVenture Partners CNS Fund I SLP, L.P. File 021-411487 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Aug 27, 2021 D Pivotal bioVenture Partners Fund II SLP, L.P. File 021-411488 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Apr 23, 2021 D Pivotal bioVenture Partners CNS Fund I, L.P. File 021-396888 | $0 | $0 | $0 (est.) The general partner (or its affiliates) is entitled to a performance allocation. The performance allocation is fully discussed in the Issuer's confidential offering materials. | None listed on this filing | EDGAR ↗ |
| Apr 23, 2021 D Pivotal bioVenture Partners Fund II, L.P. File 021-396886 | $0 | $20,000 (est.) | $0 (est.) The general partner (or its affiliates) is entitled to a performance allocation. The performance allocation is fully discussed in the Issuer's confidential offering materials. | Gateway Private Markets (HK) Limited no CRD number reported | EDGAR ↗ |
| Mar 10, 2021 D MapLight Therapeutics, Inc. File 021-391790 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 4, 2019 D MapLight Therapeutics, Inc. File 021-347993 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 22, 2019 D/A MapLight Therapeutics, Inc. File 021-334440 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 3, 2019 D Eargo, Inc. File 021-329476 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Apr 23, 2018 D/A Eargo, Inc. File 021-296767 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 30, 2017 D Outpost Medicine, LLC File 021-287636 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 30, 2016 D Bolt Biotherapeutics, Inc. File 021-271607 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 29, 2016 D Outpost Medicine, LLC File 021-260210 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 23, 2015 D Ra Pharmaceuticals, Inc. File 021-244331 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Apr 24, 2014 D/A Ceterix Orthopaedics, Inc. File 021-189370 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 23, 2012 D/A Altheos, Inc. File 021-163369 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 23, 2012 D Light Sciences Oncology Inc File 021-172323 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 10, 2011 D Light Sciences Oncology Inc File 021-161122 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 2, 2011 D/A Otonomy, Inc. File 021-147275 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 5, 2009 D Light Sciences Oncology Inc File 021-82441 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
Every issuer that named Peter Bisgaard on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.
Raised $28M from 9 investors (100% of the $28M target) as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $188.2M from 19 investors (51% of the $372.4M target) as of the latest filing. Peter is listed as director on 8 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $30M from 4 investors (30% of the $100M target) as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $1.15M from 6 investors as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $81.6M from 41 investors (100% of the $55M target) as of the latest filing. Peter is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $56M from 11 investors (100% of the $45M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $93.5M from 17 investors (100% of the $16M target) as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $29.2M from 11 investors (50% of the $58.5M target) as of the latest filing. Peter is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $31.3M from 44 investors (98% of the $31.9M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $16.6M from 6 investors (100% of the $16.6M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $35.1M from 17 investors (100% of the $1.26M target) as of the latest filing. Peter is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $24.2M from 13 investors (62% of the $38.8M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.
Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.
George Pavlov is on 10 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Vincent Sai Sing Cheung is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Richard Coles is on 55 issuers in total — a repeat sponsor. Their page lists every one.
Terry Gould is on 11 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Wende Hutton is on 18 issuers in total — a repeat sponsor. Their page lists every one.
Jeff Himawan is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Charles Warden is on 13 issuers in total — a repeat sponsor. Their page lists every one.
Brian H. Dovey is on 15 issuers in total — a repeat sponsor. Their page lists every one.
Joshua Makower is on 16 issuers in total — a repeat sponsor. Their page lists every one.
Kevin Sidow is on 7 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Heather Preston is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Rob Hopfner is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
John P. McKearn is on 17 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Peter Bisgaard. Their page shows their other deals.
One team, 5 deal companies. Peter Bisgaard is listed on 4 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Peter Bisgaard.
One team, 2 deal companies. Peter Bisgaard is listed on 1 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Peter Bisgaard.
A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.
None of the 15 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Property records are matched to companies only, never to individuals, so none are matched to Peter Bisgaard by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 15 issuers this person is listed on — nothing matched.
Websites and social links of the issuers Peter Bisgaard is listed on: none on file. No website or social profile named in Light Sciences Oncology Inc's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #241,026 of 374,652 in line (1,312 issuers searched so far). One-tap searches: Look further ↓
One-tap searches on sites we do not index ourselves, with the name pre-filled (Bellevue, WA). Each opens in a new tab; what you find there is not verified by PartnerFacts.
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Peter Bisgaard appears on a new Form D, or when a court case or SEC action is matched to them. See plans →